SCHEMBL21873038

SCHEMBL21873038

Cc1nc(-c2cnc(NC(C)C)n(C)c2=O)ccc1C(C)c1cn(C(=O)OC(C)(C)C)c2ncc(Cl)cc12

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 4/20 0.43
▸ PDGFRB P09619 3/20 0.43
▸ PDGFRA P16234 3/20 0.43
▸ LCK P06239 1/20 0.43
▸ KIT P10721 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ FLT3 P36888 1/20 0.43
▸ PTK6 Q13882 1/20 0.43
▸ AAK1 Q2M2I8 2/20 0.32
▸ KDR P35968 1/20 0.32
▸ PIK3CD O00329 1/20 0.31
▸ IRAK4 Q9NWZ3 1/20 0.31
▸ FGFR1 P11362 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21906297 0.90 CSF1R (0.43) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL21873001 0.86 CSF1R (0.44) CSF1RPDGFRBPDGFRAFLT3AAK1
SCHEMBL21872990 0.84 AAK1 (0.32) AAK1IRAK4
SCHEMBL21873122 0.80 CSF1R (0.44) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL21872988 0.76 CSF1R (0.42) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL21906344 0.76 CSF1R (0.45) CSF1RPDGFRBPDGFRAFLT3KDR
SCHEMBL21873037 0.75 CSF1R (0.43) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL21906323 0.74 IDH1 (0.33) IRAK4FGFR1
SCHEMBL21872992 0.74 CSF1R (0.44) CSF1RPDGFRBPDGFRALCKKIT
SCHEMBL21873079 0.72 CSF1R (0.43) CSF1RPDGFRBPDGFRALCKKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-11-23 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-07 — — US disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed
EP-3643715-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-04-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140431-A1 NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CSF1R, CSF3R, FSHR CSF1R 1/4885PDGFRB 149/4885PDGFRA 229/4885
US-11180495-B2 Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof CSF1R, CSF3R, FSHR CSF1R 1/4885PDGFRB 149/4885PDGFRA 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback